

ADMEDUS Ltd ABN 35 088 221 078

Share Purchase Plan

Level 1, 197 Adelaide Terrace Perth Western Australia 6000

PO Box 6879 East Perth Western Australia 6892

REGISTERED OFFICE:

T +61 (0)8 9266 0100 F +61 (0)8 9266 0199 E info.au@admedus.com

www.admedus.com

19 May 2014

Dear Shareholders,

On 12 May 2014 Admedus announced a Share Purchase Plan (**SPP**) open to eligible shareholders. This is your invitation to participate in the SPP and enclosed is a copy of the SPP booklet. Please read it carefully.

Details of how we propose to use the funds raised via this SPP and the recent \$8 million placement are outlined in the booklet.

Your Company has made solid progress since I last wrote to you, with notable achievements this year including gaining FDA approval for CardioCel[®] and positive interim Phase I results for the lead therapeutic vaccine.

Some of the many initiatives we are now focusing on include;

- increasing revenue from sales of CardioCel[®] in Europe and the US;
- seeking approvals for CardioCel[®] in other jurisdictions such as in Asia and Canada; and
- initiation of HSV-2 therapeutic vaccine Phase II trials.

The SPP Application Forms are included in the booklet and are also available on our website at: www.admedus.com

If you require information on how to complete the Application Form please contact the Share Registry on: Within Australia 1300 850 505 International +61 3 9415 4000

We look forward to your ongoing support as we continue to build an integrated healthcare company.

Yours sincerely,

Chris Catlow Chairman